Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$2.39 | -$2.39 | -$2.39 |
Q2 2024 | 1 | -$4.10 | -$4.10 | -$4.10 |
Q3 2024 | 1 | -$4.25 | -$4.25 | -$4.25 |
Q4 2024 | 2 | -$3.50 | -$3.50 | -$3.50 |
Q1 2025 | 1 | -$4.26 | -$4.26 | -$4.26 |
Q2 2025 | 1 | -$4.18 | -$4.18 | -$4.18 |
Q3 2025 | 1 | -$3.23 | -$3.23 | -$3.23 |
Q4 2025 | 1 | -$1.51 | -$1.51 | -$1.51 |
Cidara Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-2.38 earnings per share for the quarter, topping analysts' consensus estimates of $-5.22 by $2.84. The company had revenue of 0 for the quarter and had revenue of 63.91 M for the year. Cidara Therapeutics, Inc. has generated $-5 earnings per share over the last year ($-5.25 diluted earnings per share) and currently has a price-to-earnings ratio of -1.25. Cidara Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/07/2024 | Q3 2024 | -$5.22 | -$2.38 | 2.84 | $433,333 | $0 |
08/13/2024 | Q2 2024 | -$3.94 | -$19.59 | -15.65 | $1.30 M | $302,000 |
05/15/2024 | Q1 2024 | -$2.28 | $8.46 M | |||
04/22/2024 | Q4 2023 | -$0.20 | -$1.25 | -1.05 | $17.58 M | |
11/02/2023 | Q3 2023 | -$2.80 | -$1.81 | 0.99 | $8.14 M | $12.72 M |
08/03/2023 | Q2 2023 | -$1.60 | -$2.80 | -1.2 | $11.55 M | $7.61 M |
05/11/2023 | Q1 2023 | $1.20 | $0.63 | -0.57 | $25.99 M | |
03/23/2023 | Q4 2022 | -$0.20 | -$3.72 | -3.52 | $10.22 M | |
11/03/2022 | Q3 2022 | $6.00 | $3.39 | -2.61 | $28.35 M | $40.74 M |
08/09/2022 | Q2 2022 | -$5.60 | -$4.98 | 0.62 | $6.21 M | $6.22 M |
05/11/2022 | Q1 2022 | -$5.20 | -$5.41 | -0.21 | $7.11 M | |
03/07/2022 | Q4 2021 | -$6.60 | -$5.22 | 1.38 | $7.23 M | |
11/10/2021 | Q3 2021 | -$7.40 | -$7.40 | 0 | $2.94 M | $7.08 M |
08/12/2021 | Q2 2021 | -$5.40 | $3.62 | 9.02 | $12.13 M | $32.86 M |
05/13/2021 | Q1 2021 | -$3.40 | -$8.72 | -5.32 | $2.41 M | |
02/25/2021 | Q4 2020 | -$2.80 | -$9.80 | -7 | $3.73 M | |
11/05/2020 | Q3 2020 | -$9.60 | -$8.16 | 1.44 | $4.89 M | $2.42 M |
08/13/2020 | Q2 2020 | -$4.80 | -$9.00 | -4.2 | $5.29 M | $3.39 M |
05/13/2020 | Q1 2020 | -$6.80 | -$7.68 | -0.88 | $2.53 M | |
03/03/2020 | Q4 2019 | -$5.80 | -$8.43 | -2.63 | $1.82 M |
Cidara Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based off last year's report dates.
In the previous quarter, Cidara Therapeutics, Inc. (:CDTX) reported $-2.38 earnings per share (EPS) to beat the analysts' consensus estimate of $-5.22 by $2.84.
The conference call for Cidara Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Cidara Therapeutics, Inc.'s latest earnings report can be read online.
Cidara Therapeutics, Inc. (:CDTX) has a recorded annual revenue of $63.91 M.
Cidara Therapeutics, Inc. (:CDTX) has a recorded net income of $63.91 M. Cidara Therapeutics, Inc. has generated $-5.25 earnings per share over the last four quarters.
Cidara Therapeutics, Inc. (:CDTX) has a price-to-earnings ratio of -1.25 and price/earnings-to-growth ratio is 0.55.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED